Purchase this article with an account.
Hamzah Khalaf, Jeffrey Dunmire, Richard W Hertle, Berta Ponsati, Jimena Fernandez, Lluis Riera-Sans, Rachida Bouhenni; Topical Administration of Somatostatin to An Oxygen-Induced Retinopathy (OIR) Model of Retinopathy of Prematurity (ROP). Invest. Ophthalmol. Vis. Sci. 2016;57(12):6259.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Currently, treatments for retinopathy of prematurity (ROP) are invasive and while topical applications for retinal delivery of medications have been successfully developed, there are none that have been shown to treat ROP. In this pilot study, we used an Oxygen-Induced Retinopathy (OIR) mouse model of ROP to test the efficacy of topical somatostatin in reducing retinal neovascularization, an approach that was proven effective in prevention of diabetic retinopathy in animal studies and is now undergoing human trials.
Neonatal mice (C57BL/6, n=9) were exposed to 75% oxygen from postnatal day (P)7 until P12 and returned to room air (21% oxygen). Somatostatin (0.1%, n=3 and 1.0%, n=3) or vehicle (n=3) was administered once daily to both eyes from P12 to P17. Mice with body weight less than 6g at P17 were excluded. Following enucleation on P17, whole retinas were dissected, mounted, and stained with isolectin. The degree of vascular proliferation was examined by blinded observers using a fluorescent microscope and scored according to a well described retinopathy scoring system which assessed number of tufts, vessel tortuosity, vasoconstriction, and retinal hemorrhage. The total retinopathy score was compared qualitatively.
Retinal mounts from the somatostatin treated eyes showed reduced average total retinopathy score compared to those treated with vehicle (4.8 vs 6.0 respectively). In addition, the average total retinopathy score of the somatostatin 1.0% group was slightly reduced compared to that of the somatostatin 0.1% group (4.67 vs 5.0).
These results support the hypothesis that topical administration of somatostatin once daily may reduce neovascularization in the OIR mouse model. This proof-of-concept study paves the road to add novel, obviously advantageous, topical treatments for ROP. We are continuing this research by increasing the sample size in order to test our hypothesis in a more statistically rigorous fashion.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only